Session Chair Profile
Chief Business Officer VP, Market Development Clinical Genomics and Bioinformatics Qiagen
Biography
Sean works with broad range of customer, partners and collaborators in the development of genomics-guided precision medicine programs and capabilities. In this role, Sean is responsible for QIAGEN’s Clinical Genomics product portfolio offering serving the clinical decision support needs of molecular diagnostics and molecular pathology testing laboratories and healthcare provider networks globally whom are implementing genomics-based precision medicine programs and require expertise in dry lab capabilities including test interpretation and reporting. Sean led the development of QIAGEN’s recently commercialized Clinical Insight clinical decision support platform, an instrument, assay and pipeline agnostic test interpretation and reporting system that enables clinical testing labs to develop broad test menus and scale the analysis, interpretation and reporting of tests and to improve the insightfulness and action-ability of reporting to ordering physicians. Prior to QIAGEN, developed and managed Ingenuity’s marketing, sales and support operations as SVP, Global Commercial Operations and SVP, Corporate Development for Ingenuity Systems.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: Genomics guided precision medicine has great potential in terms of health management, disease prevention and improved diagnosis and treatment – however significant interpretation, translational and decision support challenges remain for molecular diagnostics labs, physicians and the patients and consumers they serve. There has been material progress in the development of better assays and wet lab capabilities but significant unmet needs and challenges remain for the insightfulness, clinical relevance and action-ability of lab reporting and physician decision support that has constrained the democratization of these promising genomics technologies. This panel, moderated by Sean P. Scott from QIAGEN, and composed of key stakeholders across the clinical workflow from ordering physician through laboratory director and pathologist to patient will provide a broad perspective on the current state of genomics-guided precision medicine and provide input on the trends, opportunities and challenges moving forward.
